PRT-001 |
PRT-001 |
Phase 3 Clinical |
Particle Therapeutics |
Hypoglycemia |
Details
|
Retatrutide |
LY-3437943 |
Phase 3 Clinical |
Eli Lilly And Company |
Diabetes Mellitus, Type 2; Renal Insufficiency; Sleep Apnea, Obstructive; Osteoarthritis, Knee; Cardiovascular Diseases; Hepatic Insufficiency; Obesity; Arthralgia; Renal Insufficiency, Chronic; Overweight; Kidney Failure, Chronic |
Details
|
Survodutide |
BI-456906; BI-456909 |
Phase 3 Clinical |
Zealand Pharma A/S |
Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Liver Diseases; Obesity; Overweight; Diabetes Mellitus |
Details
|
Pemvidutide |
ALT-801(Altimmune); SP-1373; VPD-107 |
Phase 2 Clinical |
Velocity Pharmaceutical Development |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|
Efinopegdutide |
JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 |
Phase 2 Clinical |
Hanmi Pharmaceutical Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatic Insufficiency; Obesity; Kidney Failure, Chronic |
Details
|
Efocipegtrutide |
HM-15211 |
Phase 2 Clinical |
Hanmi Pharmaceutical Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity |
Details
|
volagidemab |
AMG-477; REMD-477 |
Phase 2 Clinical |
Amgen Inc |
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin Resistance; Hyperglycemia; Diabetes Mellitus |
Details
|
Isosteviol |
ISV; STX-03 |
Phase 2 Clinical |
Stevia Pharma |
Diabetes Mellitus, Type 2 |
Details
|
Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) |
|
Phase 2 Clinical |
Pharmsynthez, Xenetic Biosciences Inc |
Diabetes Mellitus, Type 2; Obesity |
Details
|
Pegapamodutide |
WG4ID2U7FT; TT-401; LY-2944876; OPK-88003 |
Phase 2 Clinical |
Eli Lilly And Company |
Diabetes Mellitus, Type 2; Obesity |
Details
|
IONIS-GCGRRx |
IONIS-GCGRRx; ISIS-449884; ISISGCGRRx |
Phase 2 Clinical |
Ionis Pharmaceuticals Inc |
Diabetes Mellitus, Type 2 |
Details
|
Efpegerglucagon |
HM-15136 |
Phase 2 Clinical |
Hanmi Pharmaceutical Co Ltd |
Congenital Hyperinsulinism; Diabetes Mellitus, Type 2 |
Details
|
AZD9550 |
AZD9550; AZD-9550 |
Phase 2 Clinical |
Astrazeneca Plc |
Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|
MWN-101 |
MWN-101 |
Phase 2 Clinical |
Shanghai Minwei Biotechnology Co Ltd |
Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|
RBD-4988 |
RBD-4988 |
Phase 2 Clinical |
Suzhou Ribo Life Science Co Ltd |
Diabetes Mellitus, Type 2 |
Details
|
PB-718 |
PB-718 |
Phase 2 Clinical |
Peg Bio Co Ltd |
Congenital Hyperinsulinism; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight |
Details
|
Cotadutide |
MEDI-0382 |
Phase 2 Clinical |
Medimmune Llc |
Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Renal Insufficiency; Liver Cirrhosis; Hepatic Insufficiency; Diabetic Nephropathies; Renal Insufficiency, Chronic; Obesity; Diabetes Mellitus |
Details
|
NN-9277 |
NN-9277; NNC-9204-1177 |
Phase 1 Clinical |
Novo Nordisk A/S |
Obesity; Overweight; Nutritional and Metabolic Diseases |
Details
|
Glucagon (rDNA origin, Lilly) |
|
Phase 1 Clinical |
Eli Lilly And Company |
Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity |
Details
|
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) |
|
Phase 1 Clinical |
Translational Research Institute For Metabolism And Diabetes |
Obesity |
Details
|
NNC-92041706 |
NNC9204-1706; NNC-92041706; NN-9423; NNC-92041706-A |
Phase 1 Clinical |
Novo Nordisk A/S |
Obesity; Nutritional and Metabolic Diseases |
Details
|
PRT-003 |
PRT-003 |
Phase 1 Clinical |
Particle Therapeutics |
|
Details
|
SAR-441255 |
SAR-441255 |
Phase 1 Clinical |
Sanofi |
Overweight |
Details
|
Glucagon/insulin human(Abvance Therapeutics) |
ABV-100 |
Phase 1 Clinical |
Abvance Therapeutics |
Hypoglycemia |
Details
|
PB-722 |
PB722; PB-722 |
Phase 1 Clinical |
Peg Bio Co Ltd |
Congenital Hyperinsulinism |
Details
|
UBT-251 |
UBT-251; UBT251 |
Phase 1 Clinical |
Lianbang Biotechnology (Zhuhai Hengqin) Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|
TY-751 |
TY-751; TY751 |
Phase 1 Clinical |
Tianjin Remedy Research Institute |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Diabetes Mellitus |
Details
|
DA-1726 |
DA-1726 |
Phase 1 Clinical |
Dong-A ST Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity |
Details
|
DR-10624 |
DR-10624 |
Phase 1 Clinical |
Zhejiang Doer Biologics Corp |
Hypertriglyceridemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity; Overweight; Diabetes Mellitus |
Details
|
TB-001 |
TB-001; TB001 |
Phase 1 Clinical |
Shenzhen Tuwei Anchuang Technology Development Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis |
Details
|
Human glucagon(Shanghai Duomirui) |
|
Phase 1 Clinical |
Shanghai Duomirui Biotechnology Co Ltd |
Hypoglycemia |
Details
|
DD-01 |
DD-01 |
Phase 1 Clinical |
D&D Pharmatech |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|
PRT-001 |
PRT-001 |
Phase 3 Clinical |
Particle Therapeutics |
Hypoglycemia |
Details
|
Retatrutide |
LY-3437943 |
Phase 3 Clinical |
Eli Lilly And Company |
Diabetes Mellitus, Type 2; Renal Insufficiency; Sleep Apnea, Obstructive; Osteoarthritis, Knee; Cardiovascular Diseases; Hepatic Insufficiency; Obesity; Arthralgia; Renal Insufficiency, Chronic; Overweight; Kidney Failure, Chronic |
Details
|
Survodutide |
BI-456906; BI-456909 |
Phase 3 Clinical |
Zealand Pharma A/S |
Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Liver Diseases; Obesity; Overweight; Diabetes Mellitus |
Details
|
Pemvidutide |
ALT-801(Altimmune); SP-1373; VPD-107 |
Phase 2 Clinical |
Velocity Pharmaceutical Development |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|
Efinopegdutide |
JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 |
Phase 2 Clinical |
Hanmi Pharmaceutical Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatic Insufficiency; Obesity; Kidney Failure, Chronic |
Details
|
Efocipegtrutide |
HM-15211 |
Phase 2 Clinical |
Hanmi Pharmaceutical Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity |
Details
|
volagidemab |
AMG-477; REMD-477 |
Phase 2 Clinical |
Amgen Inc |
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin Resistance; Hyperglycemia; Diabetes Mellitus |
Details
|
Isosteviol |
ISV; STX-03 |
Phase 2 Clinical |
Stevia Pharma |
Diabetes Mellitus, Type 2 |
Details
|
Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) |
|
Phase 2 Clinical |
Pharmsynthez, Xenetic Biosciences Inc |
Diabetes Mellitus, Type 2; Obesity |
Details
|
Pegapamodutide |
WG4ID2U7FT; TT-401; LY-2944876; OPK-88003 |
Phase 2 Clinical |
Eli Lilly And Company |
Diabetes Mellitus, Type 2; Obesity |
Details
|
IONIS-GCGRRx |
IONIS-GCGRRx; ISIS-449884; ISISGCGRRx |
Phase 2 Clinical |
Ionis Pharmaceuticals Inc |
Diabetes Mellitus, Type 2 |
Details
|
Efpegerglucagon |
HM-15136 |
Phase 2 Clinical |
Hanmi Pharmaceutical Co Ltd |
Congenital Hyperinsulinism; Diabetes Mellitus, Type 2 |
Details
|
AZD9550 |
AZD9550; AZD-9550 |
Phase 2 Clinical |
Astrazeneca Plc |
Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|
MWN-101 |
MWN-101 |
Phase 2 Clinical |
Shanghai Minwei Biotechnology Co Ltd |
Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|
RBD-4988 |
RBD-4988 |
Phase 2 Clinical |
Suzhou Ribo Life Science Co Ltd |
Diabetes Mellitus, Type 2 |
Details
|
PB-718 |
PB-718 |
Phase 2 Clinical |
Peg Bio Co Ltd |
Congenital Hyperinsulinism; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight |
Details
|
Cotadutide |
MEDI-0382 |
Phase 2 Clinical |
Medimmune Llc |
Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Renal Insufficiency; Liver Cirrhosis; Hepatic Insufficiency; Diabetic Nephropathies; Renal Insufficiency, Chronic; Obesity; Diabetes Mellitus |
Details
|
NN-9277 |
NN-9277; NNC-9204-1177 |
Phase 1 Clinical |
Novo Nordisk A/S |
Obesity; Overweight; Nutritional and Metabolic Diseases |
Details
|
Glucagon (rDNA origin, Lilly) |
|
Phase 1 Clinical |
Eli Lilly And Company |
Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity |
Details
|
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) |
|
Phase 1 Clinical |
Translational Research Institute For Metabolism And Diabetes |
Obesity |
Details
|
NNC-92041706 |
NNC9204-1706; NNC-92041706; NN-9423; NNC-92041706-A |
Phase 1 Clinical |
Novo Nordisk A/S |
Obesity; Nutritional and Metabolic Diseases |
Details
|
PRT-003 |
PRT-003 |
Phase 1 Clinical |
Particle Therapeutics |
|
Details
|
SAR-441255 |
SAR-441255 |
Phase 1 Clinical |
Sanofi |
Overweight |
Details
|
Glucagon/insulin human(Abvance Therapeutics) |
ABV-100 |
Phase 1 Clinical |
Abvance Therapeutics |
Hypoglycemia |
Details
|
PB-722 |
PB722; PB-722 |
Phase 1 Clinical |
Peg Bio Co Ltd |
Congenital Hyperinsulinism |
Details
|
UBT-251 |
UBT-251; UBT251 |
Phase 1 Clinical |
Lianbang Biotechnology (Zhuhai Hengqin) Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|
TY-751 |
TY-751; TY751 |
Phase 1 Clinical |
Tianjin Remedy Research Institute |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Diabetes Mellitus |
Details
|
DA-1726 |
DA-1726 |
Phase 1 Clinical |
Dong-A ST Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity |
Details
|
DR-10624 |
DR-10624 |
Phase 1 Clinical |
Zhejiang Doer Biologics Corp |
Hypertriglyceridemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity; Overweight; Diabetes Mellitus |
Details
|
TB-001 |
TB-001; TB001 |
Phase 1 Clinical |
Shenzhen Tuwei Anchuang Technology Development Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis |
Details
|
Human glucagon(Shanghai Duomirui) |
|
Phase 1 Clinical |
Shanghai Duomirui Biotechnology Co Ltd |
Hypoglycemia |
Details
|
DD-01 |
DD-01 |
Phase 1 Clinical |
D&D Pharmatech |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight |
Details
|